{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:19:21Z","timestamp":1790997561390,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guizhou Provincial Eighth Batch of High-Level Innovative Talents Training Program in Guiyang","award":["No.ZKHT-GCC-[2024]018"],"award-info":[{"award-number":["No.ZKHT-GCC-[2024]018"]}]},{"name":"Guizhou Provincial Basic Research Program (Natural Science) General Program","award":["No.Qiankehe Basic MS [2025] 057"],"award-info":[{"award-number":["No.Qiankehe Basic MS [2025] 057"]}]},{"name":"Medical Research Union Fund for High-quality Health Development of Guizhou Province","award":["No.2024GZYXKYJJXM0121"],"award-info":[{"award-number":["No.2024GZYXKYJJXM0121"]}]},{"name":"Doctoral Research Initiation Funds Project of The Second People's Hospital of Guiyang","award":["No. ZEYKY-BS[2024] 05"],"award-info":[{"award-number":["No. ZEYKY-BS[2024] 05"]}]},{"name":"Science and Technology Foundation of Guizhou Provincial Health Commission","award":["No.gzwkj2025-057"],"award-info":[{"award-number":["No.gzwkj2025-057"]}]},{"name":"Cultivation Project of the National Natural Science Foundation of China (NSFC) at Guizhou Medical University","award":["No. 25NSFCP30"],"award-info":[{"award-number":["No. 25NSFCP30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05375-5","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:51:32Z","timestamp":1766415092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ANG peptide-modified exosomes loaded with oleanolic acid target GPX4 for enhanced breast cancer brain metastasis therapy"],"prefix":"10.1007","volume":"176","author":[{"given":"Guanyou","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"5375_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, SungH, Newman LA et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"5375_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-022-06799-7","volume":"197","author":"L Noteware","year":"2023","unstructured":"Noteware L, Broadwater G, Dalal N et al (2023) Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2\u2009+\u2009breast cancer. Breast Cancer Res Treat 197:425\u2013434. https:\/\/doi.org\/10.1007\/s10549-022-06799-7","journal-title":"Breast Cancer Res Treat"},{"key":"5375_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11060-024-04707-1","volume":"169","author":"C Poletes","year":"2024","unstructured":"Poletes C, Amanirad B, Santiago AT et al (2024) The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis. J Neurooncol 169:119\u2013127. https:\/\/doi.org\/10.1007\/s11060-024-04707-1","journal-title":"J Neurooncol"},{"key":"5375_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA (2016) From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15:275\u2013292. https:\/\/doi.org\/10.1038\/nrd.2015.21","journal-title":"Nat Rev Drug Discov"},{"key":"5375_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nm.4309","volume":"23","author":"J Chang","year":"2017","unstructured":"Chang J, Mancuso MR, Maier C et al (2017) Gpr124 is essential for blood\u2013brain barrier integrity in central nervous system disease. Nat Med 23:450\u2013460. https:\/\/doi.org\/10.1038\/nm.4309","journal-title":"Nat Med"},{"key":"5375_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminoncol.2020.05.003","volume":"47","author":"C Shah","year":"2020","unstructured":"Shah C, Bauer-NilsenK, McNulty RH, Vicini F (2020) Novel radiation therapy approaches for breast cancer treatment. Semin Oncol 47:209\u2013216. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.05.003","journal-title":"Semin Oncol"},{"key":"5375_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.canrad.2023.07.005","volume":"27","author":"MA Bollet","year":"2023","unstructured":"Bollet MA, Racadot S, Rivera S et al (2023) Breast cancer radiation therapy: Current questions in 2023. Cancer Radiother 27:524\u2013530. https:\/\/doi.org\/10.1016\/j.canrad.2023.07.005","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"5375_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/OTT.S293685","volume":"14","author":"Y Lv","year":"2021","unstructured":"Lv Y, Ma X, Du Y, Feng J (2021) Understanding patterns of brain metastasis in Triple-Negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther 14:589\u2013607. https:\/\/doi.org\/10.2147\/OTT.S293685","journal-title":"Onco Targets Ther"},{"key":"5375_CR9","doi-asserted-by":"publisher","first-page":"112397","DOI":"10.1016\/j.biopha.2021.112397","volume":"145","author":"ZY Tang","year":"2022","unstructured":"Tang ZY, Li Y, Tang YT et al (2022) Anticancer activity of oleanolic acid and its derivatives: recent advances in evidence, target profiling and mechanisms of action. Biomed Pharmacother 145:112397. https:\/\/doi.org\/10.1016\/j.biopha.2021.112397","journal-title":"Biomed Pharmacother"},{"key":"5375_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/10286020.2018.1464560","volume":"21","author":"YQ Meng","year":"2019","unstructured":"Meng YQ, Kuai ZY, Zhan SW et al (2019) Design, synthesis, and antitumor activity of oleanolic acid derivatives. J Asian Nat Prod Res 21:633\u2013651. https:\/\/doi.org\/10.1080\/10286020.2018.1464560","journal-title":"J Asian Nat Prod Res"},{"key":"5375_CR11","doi-asserted-by":"publisher","unstructured":"Castellano JM, Ramos-Romero S, Perona JS (2022) Oleanolic acid: Extraction, characterization and biological activity. Nutrients 14:623. https:\/\/doi.org\/10.3390\/nu14030623","DOI":"10.3390\/nu14030623"},{"key":"5375_CR12","doi-asserted-by":"publisher","unstructured":"Du S, Guan Y, Xie A et al (2023) Extracellular vesicles: a rising star for therapeutics and drug delivery. J Nanobiotechnol 21:231. https:\/\/doi.org\/10.1186\/s12951-023-01973-5","DOI":"10.1186\/s12951-023-01973-5"},{"key":"5375_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.addr.2021.04.027","volume":"174","author":"D Buschmann","year":"2021","unstructured":"Buschmann D, Mussack V, Byrd JB (2021) Separation, characterization, and standardization of extracellular vesicles for drug delivery applications. Adv Drug Deliv Rev 174:348\u2013368. https:\/\/doi.org\/10.1016\/j.addr.2021.04.027","journal-title":"Adv Drug Deliv Rev"},{"key":"5375_CR14","doi-asserted-by":"publisher","first-page":"10401","DOI":"10.3390\/ijms251910401","volume":"25","author":"S Brezgin","year":"2024","unstructured":"Brezgin S, Danilik O, Yudaeva A et al (2024) Basic guide for approaching drug delivery with extracellular vesicles. Int J Mol Sci 25:10401. https:\/\/doi.org\/10.3390\/ijms251910401","journal-title":"Int J Mol Sci"},{"key":"5375_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","volume":"159","author":"OM Elsharkasy","year":"2020","unstructured":"Elsharkasy OM, Nordin JZ, Hagey DW et al (2020) Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev 159:332\u2013343. https:\/\/doi.org\/10.1016\/j.addr.2020.04.004","journal-title":"Adv Drug Deliv Rev"},{"key":"5375_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.semcancer.2020.08.007","volume":"80","author":"M Pirisinu","year":"2022","unstructured":"Pirisinu M, Pham TC, Zhang DX et al (2022) Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. Semin Cancer Biol 80:340\u2013355. https:\/\/doi.org\/10.1016\/j.semcancer.2020.08.007","journal-title":"Sem Cancer Biol"},{"key":"5375_CR17","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.3390\/molecules27196696","volume":"27","author":"AC di Polidoro","year":"2022","unstructured":"diPolidoro AC, Cafarchio A, Vecchione D et al (2022) Revealing Angiopep-2\/LRP1 molecular interaction for optimal delivery to glioblastoma (GBM). Molecules 27:6696. https:\/\/doi.org\/10.3390\/molecules27196696","journal-title":"Molecules"},{"key":"5375_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/cancers13030503","volume":"13","author":"A di Costagliola","year":"2021","unstructured":"Costagliola di Polidoro A, Zambito G, Haeck J et al (2021) Theranostic design of Angiopep-2 conjugated hyaluronic acid nanoparticles (Thera-ANG-cHANPs) for dual targeting and boosted imaging of glioma cells. Cancers 13:503. https:\/\/doi.org\/10.3390\/cancers13030503","journal-title":"Cancers"},{"key":"5375_CR19","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1039\/d3cs00001j","volume":"52","author":"N Kang","year":"2023","unstructured":"Kang N, Son S, Min S et al (2023) Stimuli-responsive ferroptosis for cancer therapy. Chem Soc Rev 52:3955\u20133972. https:\/\/doi.org\/10.1039\/d3cs00001j","journal-title":"Chem Soc Rev"},{"key":"5375_CR20","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu Z, Wang X, Sun W et al (2023) RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. Redox Biol 68:102952. https:\/\/doi.org\/10.1016\/j.redox.2023","journal-title":"Redox Biol"},{"key":"5375_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/antiox14050598","volume":"14","author":"A G\u00fcnther","year":"2025","unstructured":"G\u00fcnther A, Bednarczyk-Cwynar B (2025) Oleanolic acid: A promising antioxidant\u2014sources, mechanisms of action, therapeutic potential, and enhancement of bioactivity. Antioxidants 14:598. https:\/\/doi.org\/10.3390\/antiox14050598","journal-title":"Antioxidants"},{"key":"5375_CR22","doi-asserted-by":"publisher","first-page":"15267","DOI":"10.18632\/aging.205349","volume":"15","author":"H Xu","year":"2023","unstructured":"Xu H, Yuan Q, Wu Z et al (2023) Integrative transcriptome and single-cell sequencing technology analysis of the potential therapeutic benefits of oleanolic acid in liver injury and liver cancer. Aging 15:15267\u201315286. https:\/\/doi.org\/10.18632\/aging.205349","journal-title":"Aging"},{"key":"5375_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.4155\/fmc-2023-0041","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Yang D, Li X et al (2023) Synthesis and biological evaluation of oleanolic acid derivatives with electrophilic warheads as antitumor agents. Future Med Chem 15:769\u2013790. https:\/\/doi.org\/10.4155\/fmc-2023-0041","journal-title":"Future Med Chem"},{"key":"5375_CR24","doi-asserted-by":"publisher","unstructured":"Lee KT, Lieu AS, Lin CL et al (2025) Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest. Med Oncol 42:353. https:\/\/doi.org\/10.1007\/s12032-025-02875-2","DOI":"10.1007\/s12032-025-02875-2"},{"key":"5375_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.34172\/apb.2023.057","volume":"13","author":"CB Avc\u0131","year":"2023","unstructured":"Avc\u0131 CB, Sogutlu F, Pinar Ozates N, et al (2023) Enhanced anti-cancer potency using a combination of oleanolic acid and maslinic acid to control treatment resistance in breast cancer. Adv Pharm Bull 13:611\u2013620. https:\/\/doi.org\/10.34172\/apb.2023.057","journal-title":"Adv Pharm Bull"},{"key":"5375_CR26","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/cancers16193367","volume":"16","author":"KB Gupta","year":"2024","unstructured":"Gupta KB, Gao J, Li X, et al (2024) Cytotoxic autophagy: a novel treatment paradigm against breast cancer using oleanolic acid and ursolic acid. Cancers 16:3367. https:\/\/doi.org\/10.3390\/cancers16193367","journal-title":"Cancers"},{"key":"5375_CR27","doi-asserted-by":"publisher","unstructured":"Li Q, Hu W, Huang Q et al (2023) MiR146a-loaded engineered exosomes released from silk fibroin patch promote diabetic wound healing by targeting IRAK1. Sig Transduct Target Ther 8:62. https:\/\/doi.org\/10.1038\/s41392-022-01263-w","DOI":"10.1038\/s41392-022-01263-w"},{"key":"5375_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1517\/17425247.2016.1126245","volume":"13","author":"A Mokhtarzadeh","year":"2016","unstructured":"Mokhtarzadeh A, Parhiz H, Hashemi M et al (2016) P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells. Expert Opin Drug Deliv 13:477\u2013491. https:\/\/doi.org\/10.1517\/17425247.2016.1126245","journal-title":"Expert Opin Drug Deliv"},{"key":"5375_CR29","doi-asserted-by":"publisher","unstructured":"Eigenmann DE, Xue G, Kim KS et al (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC\/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood\u2013brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33. https:\/\/doi.org\/10.1186\/2045-8118-10-33","DOI":"10.1186\/2045-8118-10-33"},{"key":"5375_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2147\/IJN.S395246","volume":"18","author":"H Li","year":"2023","unstructured":"Li H, Ding Y, Huang J et al (2023) Angiopep-2 modified exosomes load rifampicin with potential for treating central nervous system tuberculosis. Int J Nanomedicine 18:489\u2013503. https:\/\/doi.org\/10.2147\/IJN.S395246","journal-title":"Int J Nanomedicine"},{"key":"5375_CR31","doi-asserted-by":"publisher","unstructured":"Dasgupta A, Sun T, Rama E et al (2023) Transferrin Receptor-Targeted Nonspherical microbubbles for Blood\u2013Brain barrier sonopermeation. Adv Mater 35. https:\/\/doi.org\/10.1002\/adma.202308150","DOI":"10.1002\/adma.202308150"},{"key":"5375_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17425247.2022.2083106","volume":"19","author":"S Mojarad-Jabali","year":"2022","unstructured":"Mojarad-Jabali S, Mahdinloo S, Farshbaf M et al (2022) Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer. Expert Opin Drug Deliv 19:685\u2013705. https:\/\/doi.org\/10.1080\/17425247.2022.2083106","journal-title":"Expert Opin Drug Deliv"},{"key":"5375_CR33","doi-asserted-by":"publisher","first-page":"123656","DOI":"10.1016\/j.ijpharm.2023.123656","volume":"649","author":"K Haroon","year":"2024","unstructured":"Haroon K, Zheng H, Wu S et al (2024) Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury. Int J Pharm 649:123656. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123656","journal-title":"Int J Pharm"},{"key":"5375_CR34","doi-asserted-by":"publisher","first-page":"150260","DOI":"10.1016\/j.bbrc.2024.150260","volume":"725","author":"Y Li","year":"2024","unstructured":"Li Y, Chen Z, Guo J et al (2024) Enhanced brain-targeting and efficacy of Cannabidiol via RVG-Exo\/CBD nanodelivery system. Biochem Biophys Res Commun 725:150260. https:\/\/doi.org\/10.1016\/j.bbrc.2024.150260","journal-title":"Biochem Biophys Res Commun"},{"key":"5375_CR35","doi-asserted-by":"publisher","first-page":"1341-1354","DOI":"10.1016\/j.apsb.2020.10.015","volume":"11","author":"NU Khan","year":"2021","unstructured":"Khan NU, Ni J, Ju X et al (2021) Escape from abluminal LRP1-mediated clearance for boosted nanoparticle brain delivery and brain metastasis treatment. Acta pharm Sin B 11:1341\u20131354. https:\/\/doi.org\/10.1016\/j.apsb.2020.10.015","journal-title":"Acta pharm Sin B"},{"key":"5375_CR36","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ymthe.2021.03.022","volume":"29","author":"H Wang","year":"2021","unstructured":"Wang H, Cheng Y, Mao, C et al (2021) Emerging mechanisms and targeted therapy of ferroptosis in cancer. Mol Ther 29:2185\u20132208. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.022","journal-title":"Mol Ther"},{"key":"5375_CR37","doi-asserted-by":"publisher","first-page":"247-250","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ et al (2017) Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551:247\u2013250. https:\/\/doi.org\/10.1038\/nature24297","journal-title":"Nature"},{"key":"5375_CR38","doi-asserted-by":"publisher","unstructured":"Park SY, Jeong KJ, Poire A et al (2023) Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death Dis 14:532. https:\/\/doi.org\/10.1038\/s41419-023-06042-1","DOI":"10.1038\/s41419-023-06042-1"},{"key":"5375_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.apsb.2022.03.026","volume":"13","author":"Z Luo","year":"2023","unstructured":"Luo Z, Wu S, Zhou J et al (2023) All-stage targeted therapy for the brain metastasis from triple-negative breast cancer. Acta Pharm Sinica B 13:359\u2013371. https:\/\/doi.org\/10.1016\/j.apsb.2022.03.026","journal-title":"Acta Pharm Sinica B"},{"key":"5375_CR40","doi-asserted-by":"publisher","first-page":"200824","DOI":"10.1016\/j.omton.2024.200824","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang J, Tian L, Barr T et al (2024) Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide. Mol Ther Oncol 32:200824. https:\/\/doi.org\/10.1016\/j.omton.2024.200824","journal-title":"Mol Ther Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05375-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:47:11Z","timestamp":1769773631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05375-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5375"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05375-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Animal Ethics Committee of Guizhou Medical University (Approval No. 2502450). All procedures were conducted in compliance with relevant animal welfare guidelines and regulations to ensure ethical treatment of the animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}